Krystal Biotech



Krystal Biotech

Vyjuvek HCPCS:


HCPCS Code Descriptor:

Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml


J Code

Vyjuvek NDCs:


Primary Type:

Genetic Disorder

Generic/Specialty Status:


Route of Administration:

Topical application

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Vyjuvek:

VYJUVEK is a Genetic Disorder drug manufactured by Krystal Biotech and administered via the Topical application route of administration. The J Code: J3401 is aligned to the drug VYJUVEK.

Vyjuvek is a topical medication used to treat wounds in patients with dystrophic epidermolysis bullosa, or DEB. DEB is a serious genetic disorder that is caused by a mutation to the COL7A1 gene. The COL7A1 gene is responsible for the production of a collagen protein necessary to bind the dermis, or the inner layer of the skin, to the epidermis, or the outer layer of the skin. When this protein is absent, the skin becomes extremely fragile, and can be torn or blistered by normal daily activities. Vyjuvek is a vector-based gene therapy that can help treat these wounds by restoring healthy copies of the COL7A1 gene and producing functional collagen protein.


J3401 Added Date:

January 1, 2024

J3401 Effective Date:

January 1, 2024

J3401 Termination Date:

HCPCS Active

Vyjuvek billing and coding information can be found through Krystal Biotech at the link below:
Vyjuvek patient assistance information can be found through Krystal Connect at the URL:
VYJUVEK prescribing information can be found at the link below:
Information regarding VYJUVEK’s side effects can be found at MedlinePlus